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Background
We demonstrated in a phase 1 trial that an immuno-
therapy (AGS-004) consisting of a monocyte-derived den-
dritic cells (DC) and RNA encoding autologous HIV
antigens (Gag, Nef, Rev, Vpr) derived from the patient's
own pre-ART plasma induced immunogenicity in most
patients. Based on these results a multicenter phase 2 trial
was implemented to assess the safety and proportion of
patients demonstrating viral load (VL) < 1000, < 5000 and
< 10,000 copies/ml during the 12 week ART structured
treatment interruption (STI).
Methods
Subjects on their initial ART regimen with VL < 50 copies/
ml, CD4 > 450 cells/μl, CD4 nadir > 200 cells/μl and a
pre-ART VL > 10,000 to 500,000 copies/ml were eligible.
The treatment consists of 4 intradermal AGS-004 doses
administered monthly in combination with ART followed
by two more doses during the 12 week STI. Subjects who
participated in the phase 1 study were included and
received a second cycle of AGS-004. Subjects may con-
tinue AGS-004 booster administration if VL remains <
10,000 copies/ml.
Results
33 subjects were enrolled from 11 Canadian sites, and
AGS-004 successfully manufactured and administered to
21 subjects. 9 subjects have successfully completed 12
weeks of STI. The immunotherapy related AEs were Grade
1 or 2 flu-like, GI symptoms, fatigue, and injection site
reactions. During the STI, no reports of autoimmunity or
AIDS defining events were observed. After an initial viral
rebound, 4 out of 9 subjects had > 2 instances of VL meas-
ures < 1000 copies/mL when assessed every 2 weeks dur-
ing the STI. At week 12 of STI 5 subjects had viral loads <
10,000 copies/ml with CD4 > 350 cells/μl including 4
subjects with viral loads < 5000 copies/ml.
Conclusion
Results from this phase 2 autologous immunotherapy
trial demonstrated that this therapy is safe and induced
partial control of VL when compared to pre-ART VL dur-
ing the 12-week STI.
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